 |
BioCentury This WeekAuthor: BioCentury
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem. Language: en-us Genres: Business, Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Episode 383
Monday, 24 August, 2026
A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the vaccine’s prospects and the broader implications. The analysts also discuss Roche/Genentech’s deal with Hanmi, which will add to the MNC’s obesity pipeline an asset that the pharma believes could be first in class, and the White House's pick of a Trump loyalist to lead FDA – a move that has revived questions of the agency's independence.View full story: https://www.biocentury.com/article/660596#CancerVaccines #Obesity #FDA #Oncology #DrugDevelopment00:00 - Introduction03:03 - Moderna11:12 - Genentech obesity deal15:08 - Trump's FDA pickTo submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
